Fig. 9.
Effect of ancrod therapy on α2-plasmin inhibitor, PAI-1, and prothrombin fragment F1.2
Results show the time course of ancrod treatment of all 12 subjects (mean, SD, 95th percentile). (A) α2-Plasmin inhibitor measured by chromogenic assay. (B) PAI-1 measured by ELISA. (C) Prothrombin fragment F1.2 measured by ELISA. The increase in plasmin-α2-plasmin inbibitor complex is mirrored by a reduction in plasma levels of α2-plasmin inhibitor. PAI-1 remains nearly unchanged during ancrod treatment. Ancrod infusion does not result in an increase in prothrombin fragment F1.2 levels.
